Corcept Therapeutics Inc. launched a new front in its bid to shield its only drug, Korlym, from facing generic competition, suing in New Jersey federal court to stop Teva Pharmaceuticals USA Inc.'s plans to make a copy of the Cushing’s syndrome treatment.
Teva is trying to prematurely launch its own drug before two Corcept patents covering Korlym—US Patent Nos. 10,842,800 and 10,842,801—expire, according to Corcept’s Friday complaint. Bloomberg Law estimates that the patents will expire in 2037 and 2032, respectively.
Korlym is prescribed to treat patients with Cushing’s syndrome, which is caused by an excess of the hormone ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.